Semax: Evidence, Legal Status, and Safety
Semax is a synthetic nootropic peptide developed in Russia that raises BDNF (brain-derived neurotrophic factor) and has real published human trial data, including a controlled stroke-recovery study, unlike most research peptides. But that evidence base is Russian, has not been replicated in Western randomized trials, and Semax has no FDA approval or legal marketing pathway for any use in the US.
Understand what's actually being sold A synthetic heptapeptide derived from ACTH(4-10), developed at the Institute of Molecular Genetics, Russian Academy of Sciences; registered as a pharmaceutical (intranasal drops) in Russia and Ukraine since the 1990s for stroke recovery, optic nerve disease, and cognitive complaints.
Semax is not a general wellness supplement; it was developed and registered as a specific-indication pharmaceutical in specific countries.
See what the human evidence actually shows A controlled trial of 110 ischemic-stroke patients found intranasal Semax raised plasma BDNF and was associated with faster motor-function recovery and better Barthel Index scores. A separate acute-stroke RCT is referenced in some third-party summaries but could not be independently confirmed against a PubMed or DOI record; it is not cited here as settled.
Real controlled human trial data puts Semax ahead of most research peptides, but a single, non-replicated, non-Western trial is not the same as an established evidence base.
Know the limits of this evidence This entire evidence base is Russian, published mostly in Russian-language journals, and has not been replicated in a large Western randomized trial. Treat the stroke-recovery finding as real but not internationally confirmed.
Non-replication in independent, Western trials is a meaningful evidence gap, not a technicality.
Know where it actually stands Not FDA-approved for any use in the US. On 24 Jul 2026, the FDA's Pharmacy Compounding Advisory Committee recommended Semax for compounding, but that recommendation is advisory only: no US prescription or compounding pathway exists today, and formal rulemaking has not started. Sold in the US as an unregulated research chemical.
Registration as a pharmaceutical in Russia and Ukraine does not extend to any legal status in the US.
Know the real risk Reported intranasal doses in Russian trials ranged roughly 600mcg to 12mg per day for up to 10 days without reported adverse events in that literature. No independent US safety review exists.
A safety record inside one country's trial literature is not the same as an independent regulatory safety review.
A controlled trial of 110 ischemic-stroke patients found intranasal Semax raised plasma BDNF and was associated with faster motor-function recovery and better Barthel Index scores.
View sources
Semax stroke-recovery and BDNF trial
Not medical advice. This page is for education only and is not a substitute for professional medical care. Consult a qualified clinician before changing your health routine.
Editorial disclosure. This protocol is written and fact-checked by the YourProtocol editorial team directly from the primary sources cited below; it is not written or reviewed by any outside expert.
Is this for you
- Anyone considering Semax who wants the honest evidence before discussing it with a clinician
- Readers researching nootropic peptides who have seen stroke-recovery or BDNF claims
- Readers comparing Russian-registered pharmaceuticals to FDA-approved or purely preclinical peptides
Cautions
- Evidence base is Russian, published mostly in Russian-language journals, and not independently replicated in a Western randomized trial
- A second, frequently-cited acute-stroke RCT could not be independently confirmed against a PubMed or DOI record in this research pass and is not cited here as settled
- Not FDA-approved for any use in the US; sold in the US as an unregulated research chemical
- Educational only, not medical advice